OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Issue Information	357
	131
John Michael Walshe (April 24, 1920–October 14, 2022)	95
Body Mass Index Is Significantly Associated With Disease Severity in Spinocerebellar Ataxia Type 2 Patients	86
In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's Disease	81
Severe Dyskinesia After Administration of SARS‐CoV2 mRNA Vaccine in Parkinson's Disease	81
Has Parkinson Disease Gone to the Dogs?	78
Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422	73
Strong Correlation between Clinical Improvement and Low‐Frequency Oscillations in Pediatric Dystonia	72
DBSMatchMaker: Connecting Clinicians Globally for Deep Brain Stimulation in Rare Diseases	69
GNAO1 Mutations Affecting the N‐Terminal α‐Helix of Gαo Lead to Parkinsonism	68
Highlighting the Dystonic Phenotype Related to GNAO1	68
Reply to: “Is Gait Dysfunction Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?”	67
Unraveling the Twist: Spatial Navigational Challenges in Cervical Dystonia	67
Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease	66
Covid‐19 Infection and Parkinsonism: Is There a Link?	64
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait	62
Mortality of People with Parkinson's Disease in a Large UK‐Based Cohort Study: Time Trends and Relationship to Disease Duration	61
Confirmation of a Causal Role for SHQ1 Variants in Early Infantile‐Onset Recessive Dystonia	60
Reply to Letter to the Editor: “Disease Progression in Multiple System Atrophy: The Value of Clinical Cohorts with Long Follow‐Up”	59
Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease	59
Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease	58
Reply to: Comment on “Summing MDS‐UPDRS Parts 1 + 2 (Non‐motor and Motor Experience of Daily Living): The Patient's Voice”	58
Reply to ‘Comment on Martino et al. ‘Scales for Antipsychotic‐Associated Movement Disorders: Systematic Review, Critique, and Recommendations’”	57
Issue Information	56

Reply to: “Is Conscientiousness Related to the Risk of Parkinson's Disease?”	55
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study	53
Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update	53
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations	51
HbA1c and Motor Outcome in Parkinson's Disease in the Mark‐PD Study	50
Movement Disorders: Volume 38, Number 3, March 2023	49
July Infographic	48
Movement Disorders: Volume 37, Number 7, July 2022	48
Movement Disorders: Volume 37, Number 12, December 2022	47
	47
Editor's Note	47
Reply to: “The First Allogeneic Hematopoietic Stem Cell Transplantation in a Polish Patient with Adult‐Onset Leukoencephalopathy with Spheroids and Pigmented Glia”	47
Education, Other Topics	46
Keyword index	46
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease	45
Movement Disorders: Volume 36, Number 7, July 2021	45
	45
Movement Disorders: Volume 36, Number 5, May 2021	45
Issue Information	45
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early	44
Evaluation of SORL1 in Lewy Body Dementia Identifies No Significant Associations	44
Cost‐Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease	44
	43
Reply to: Comparing VUS and AUS: Parallels and Differences in Neurogenetics and Neuroimmunology	42
Harnessing Transcriptomics to Decipher Dystonia Pathogenesis	41
Reply to: “Parkinson's Disease, Premature Mortality, and Amygdala”	41
Movement Disorders: Volume 36, Number 12, December 2021	41
The Ratio of Expanded to Normal Ataxin 3 in Peripheral Blood Mononuclear Cells Correlates with the Age at Onset in Spinocerebellar Ataxia Type 3	41
Eye‐of‐Tiger Sign in Globus Pallidus: A Novel Radiological Feature of Spinocerebellar Ataxia Type 28	41
Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected	40
Risk Disclosure in Prodromal Parkinson's Disease	39
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?	38
Neuropathology of McLeod Syndrome	38
Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson's Disease: A Diagnostic Accuracy Study	37
Reply to: “Age‐Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK‐PD)”	36
	36
Reply to: “Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1‐Associated Parkinson's Disease”	36
Movement Disorders: Volume 37, Number 2, February 2022	36
Plasma Glutathione and Prodromal Parkinson's Disease Probability	35
Abstracts	35
Motor Features in a Peruvian Cohort of Parkinson's Disease Patients	34
Multimodal Longitudinal Neurophysiological Investigations in Dopa‐Responsive Dystonia	34
Efficacy of Caffeine in ADCY5‐Related Dyskinesia: A Retrospective Study	34
Reply to: “HbA1c and Motor Outcome in Parkinson's Disease in the Mark‐PD Study”	34
Promoting Gender Inclusivity: A Questionnaire for Women's Health Factors in Parkinson's Disease	33
Impact of COVID‐19 on Patient Care, Training, and Research in Movement Disorders in MDS‐AOS Region	33
Neuron‐Derived Misfolded α‐Synuclein in Blood: A Potential Biomarker for Parkinson's Disease?	33
Issue Information	33
Astrocyte Responses Influence Local Effects of Whole‐Brain Magnetic Stimulation in Parkinsonian Rats	33
Lateralized Effect of Thalamic Deep Brain Stimulation Location on Verbal Abstraction	32

An MDS Evidence‐Based Review on Treatments for Huntington's Disease	32
Changes in Body Composition Before and After Parkinson's Disease Diagnosis	32
Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R‐Related Leukoencephalopathy	32
A TNR Frameshift Variant in Weimaraner Dogs with an Exercise‐Induced Paroxysmal Movement Disorder	32
Detection and Characterization of a De Novo Alu Retrotransposition Event Causing NKX2‐1‐Related Disorder	32
Stressing the Importance of Cholinergic Interneurons in Striatal Function	31
Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease	31
Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s Disease	31
Genetics and Metabolic Diseases	31
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model	31
Reply to: Juvenile PLA2G6‐parkinsonism due to Indian ‘Asian’ p.R741Q mutation, and response to STN DBS	31
Cognition and Psychiatric Disturbances	31
Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers	30
Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk	30
Striking While the Iron is Hot: The Role of Prosaposin (PSAP) in Parkinson's Disease	30
Cerebral Microbleeds in Fragile X–Associated Tremor/Ataxia Syndrome	30
Cell Therapy for Huntington's Disease: Learning from Failure	30
Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease	30
Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders	30
Cerebrospinal FluidBiomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders	29
Issue Information	29
Issue Information	29
RFC1‐Related Disorder: In Vivo Evaluation of Spinal Cord Damage	29
ANO3 as a Cause of Early‐Onset Chorea Combined with Dystonia: Illustration of Phenotypic Evolution	29
October Infographic	29
Unraveling the Missing Heritability in Late‐Onset Cerebellar Ataxia	29
Comparison of Transcranial Sonography and [¹⁸F]‐Fluorodopa PET Imaging in GBA1 Mutation Carriers	28
Differences Among Native Hawaiian, Asian, and White Patients with Progressive Supranuclear Palsy	28
Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives	27
Fostering Voice Objective Analysis in Patients with Movement Disorders	27
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway	27
Exploring THAP11 Repeat Expansion beyond Chinese‐Ancestry Cohorts: An Examination of 1000 Genomes and UK Biobank Data	27
Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy	27
	27
Ca²⁺–Calmodulin–Calcineurin Signaling Modulates α‐Synuclein Transmission	27
Parkinson's Kinesia Paradoxa Is Not a Paradox	26
Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities	26
Variable Age at Onset in AOPEP‐Associated Dystonia	26
Magnetic Resonance–Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early‐Stage Tremor‐Dominant Parkinson's Disease: A Pilot Study	26
	26
Issue Information	26
Device‐Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta‐Analysis	26
Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder	25
Long‐Term Globus Pallidus Internus Deep Brain Stimulation in Pediatric Non‐Degenerative Dystonia: A Cohort Study and a Meta‐Analysis	25
YY1: A New Gene for Childhood Onset Dystonia with Prominent Oromandibular‐Laryngeal Involvement?	25
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism	25
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property	24
Issue Information	24
Movement Disorders: Volume 38, Number 7, July 2023	24
Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease	24
High Praise for Domen and Colleagues	24
Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds	24
Epidemiology and Rating Scales	24
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism	24
Issue Information	23
HOMER‐3 Antibodies Were Not Detected in Two German Cohorts of Patients with Multiple System Atrophy	23
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy	23
The South African Parkinson's Disease Study Collection	23
Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study	23
Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design	23
A Critical Investigation of Cerebellar Associative Learning in Isolated Dystonia	23
Microstructural Abnormalities of the Dentatorubrothalamic Tract in Cervical Dystonia	23
Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)	23
Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease?	22
Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression	22
Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology‐Proven Cases	22
An Exploratory, Randomized, Double‐Blind Clinical Trial of Dipraglurant for Blepharospasm	22
	22
Corticospinal Suppression Underlying Intact Movement Preparation Fades in Parkinson's Disease	22
A Multi‐center Genome‐wide Association Study of Cervical Dystonia	22
Negative Myoclonus: Neurophysiological Study and Clinical Impact in Progressive Myoclonus Ataxia	22
Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy–Richardson Syndrome	22
A Unified Framework for Evidence‐Based Diagnostic Criteria Programs in Movement Disorders	22
Measuring Tremor—A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating	22
Preparing for Disease‐Modification Trials in Degenerative Cerebellar Ataxias: Which Endpoints to Choose?	22
Genetic Testing in Parkinson's Disease	22
Movement Disorders: Volume 39, Number 4, April 2024	22
Sphingolipid and Phospholipid Levels Are Altered in Human Brain in Chorea‐Acanthocytosis	22
X‐Linked Dystonia‐Parkinsonism (“Lubag”) May Present with Peripheral Synucleinopathy	22
Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta‐Analysis	22

Dry‐Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation	22
Pathway‐Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease	22
The Logic and Pitfalls of Parkinson's as Brain‐ Versus Body‐First Subtypes	21
European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies	21
Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy	21
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease	21
More Than Just the Level of Consciousness: Comparing Asleep and Awake Deep Brain Stimulation	21
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers	21
Identification of a DAGLB Mutation in a Non‐Chinese Patient with Parkinson's Disease	21
Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants	21
Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial	21
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12	20
Diagnostic Criteria for Primary Tic Disorders: Time for Reappraisal	20
Patients' Perspective of Dystonia Symptoms during the SARS‐CoV‐2 Pandemic	20
Mild Motor Signs in Healthy Aging Are Associated with Lower Synaptic Density in the Brain	20
Neuromelanin‐Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism	20
Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD) Shares Similar Fecal Short‐Chain Fatty Acid Alterations with Multiple System Atrophy (MSA) and Parkinson's Disease	20
Acute Hemichorea‐Hemiballismus Following COVID‐19 (AZD1222) Vaccination	20
Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations	20
The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait—A Randomized Motion Sensor Study	20
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study	20
Subclinical Epileptiform Activity in Dementia with Lewy Bodies	20
	19
In Memoriam Mahlon R. DeLong (1938–2024)	19
A Novel Variant of ATP5MC3 Associated with Both Dystonia and Spastic Paraplegia	19
Dysregulated Cerebrospinal Fluid Proteome of Spinocerebellar Ataxia Type 2 and its Clinical Implications	19
Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease	19
α‐Synuclein Seed Amplification Assays from Blood‐Based Extracellular Vesicles in Parkinson's Disease: An Evaluation of the Evidence	19
Gamified Closed‐Loop Intervention Enhances Tic Suppression in Children: A Randomized Trial	19
Editor's Note	19
Magnetic Resonance Imaging–Guided Focused Ultrasound Thalamotomy in Spinocerebellar Ataxia Type 12	19
Functional Movement Disorder as a Prodromal Symptom of Parkinson's Disease—Clinical and Pathophysiological Insights	18
Epidemiology of Huntington's Disease in Latin America: A Systematic Review and Meta‐Analysis	18
Probabilistic Refinement of Focused Ultrasound Thalamotomy Targeting for Parkinson's Disease Tremor	18
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia	18
Response to Mortimer et al. “Clinical and molecular profiling in GNAO1 permits phenotype–genotype correlation”	18
November Infographic	18
	18
Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics	18
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study	17
Adaptive Long‐Read Sequencing Reveals GGC Repeat Expansion in ZFHX3 Associated with Spinocerebellar Ataxia Type 4	17
Metagenomic Analysis Reveals Large‐Scale Disruptions of the Gut Microbiome in Parkinson's Disease	17
Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy	17
Biomarker‐Based Approach to α‐Synucleinopathies: Lessons from Neuropathology	17
Smartphone Voice Calls Provide Early Biomarkers of Parkinsonism in Rapid Eye Movement Sleep Behavior Disorder	17
Prokineticin‐2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients	17
Reply to: “THAP11 CAG Expansion Beyond Chinese‐Ancestry Cohorts: An Examination of 1000 Genomes and UK Biobank”	17
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial	17
Development and Validation of the Dystonia‐Pain Classification System: A Multicenter Study	17
Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy	17
Role of Bβ1 overexpression in the pathogenesis of SCA12	17
Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease	17
Social Cognition in Parkinson's Disease after Focused Ultrasound Subthalamotomy: A Controlled Study	17
Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta‐Analysis	17
A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design	17
A Pilot Group Cognitive Behavioral Therapy Telehealth Intervention for Functional Movement Disorder	17
Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial	16
September Infographic	16
Resting‐State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease‐Mild Cognitive Impairment	16
	16
Translational Pharmacology of PRAX‐944, a Novel T‐Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor	16
Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease	16
A New Case Series Suggests That SCA48 (ATX/STUB1) Is Primarily a Monogenic Disorder	16
Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms	16
Responsive Deep Brain Stimulation: A New Hope for Controlling Stimulation‐Induced Dysarthria in Essential Tremor	16
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	16
Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease	16
Long‐Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early‐Onset Parkinson's Disease	16
Clinical and Molecular Profiling in GNAO1 Permits Phenotype–Genotype Correlation	16
Long‐Term Follow‐Up of Pediatric Patients with Dyskinetic Cerebral Palsy and Deep Brain Stimulation	16
Reply to: “CAG Repeat Expansion in THAP11 is Not Detected in a Cohort with Spinocerebellar Ataxia from Hokkaido, the Northernmost Island of Japan”	16
Sodium Oxybate in Alcohol‐Responsive Essential Tremor of Voice: An Open‐Label Phase II Study	16
Severe Acute Motor Exacerbations (SAME) across Metabolic, Developmental and Genetic Disorders	16
Claims‐Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease	15
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans	15
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease	15
Blocking the Self‐Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition	15
Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease	15
The Impact of Type 2 Diabetes in Parkinson's Disease	15
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters	15
Diagnostic Value of Salivary Real‐Time Quaking‐Induced Conversion in Parkinson's Disease and Multiple System Atrophy	15
Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease	15
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease	15
The Genetic Drivers of Juvenile, Young, and Early‐Onset Parkinson's Disease in India	15
Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes	15
Evaluation of a Structured Screening Assessment to Detect Isolated Rapid Eye Movement Sleep Behavior Disorder	15
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure	15
Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach	15
Dissolving the Complex Role Aggregation Plays in Neurodegenerative Disease	15
Neuroticism and Risk of Parkinson's Disease: A Meta‐Analysis	15
Gain‐of‐Function KIDINS220 Variants Disrupt Neuronal Development and Cause Cerebral Palsy	15
Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease	15
Sensitivity to Change and Patient‐Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data‐Driven Analysis	15
Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [¹⁸F]‐FEMPA PET Study	15
Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐Analysis	15